• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲血统人群中多基因评分分布的差异:对乳腺癌风险预测的影响。

Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction.

作者信息

Yiangou Kristia, Mavaddat Nasim, Dennis Joe, Zanti Maria, Wang Qin, Bolla Manjeet K, Abubakar Mustapha, Ahearn Thomas U, Andrulis Irene L, Anton-Culver Hoda, Antonenkova Natalia N, Arndt Volker, Aronson Kristan J, Augustinsson Annelie, Baten Adinda, Behrens Sabine, Bermisheva Marina, de Gonzalez Amy Berrington, Białkowska Katarzyna, Boddicker Nicholas, Bodelon Clara, Bogdanova Natalia V, Bojesen Stig E, Brantley Kristen D, Brauch Hiltrud, Brenner Hermann, Camp Nicola J, Canzian Federico, Castelao Jose E, Cessna Melissa H, Chang-Claude Jenny, Chenevix-Trench Georgia, Chung Wendy K, Colonna Sarah V, Couch Fergus J, Cox Angela, Cross Simon S, Czene Kamila, Daly Mary B, Devilee Peter, Dörk Thilo, Dunning Alison M, Eccles Diana M, Eliassen A Heather, Engel Christoph, Eriksson Mikael, Evans D Gareth, Fasching Peter A, Fletcher Olivia, Flyger Henrik, Fritschi Lin, Gago-Dominguez Manuela, Gentry-Maharaj Aleksandra, González-Neira Anna, Guénel Pascal, Hahnen Eric, Haiman Christopher A, Hamann Ute, Hartikainen Jaana M, Ho Vikki, Hodge James, Hollestelle Antoinette, Honisch Ellen, Hooning Maartje J, Hoppe Reiner, Hopper John L, Howell Sacha, Howell Anthony, Jakovchevska Simona, Jakubowska Anna, Jernström Helena, Johnson Nichola, Kaaks Rudolf, Khusnutdinova Elza K, Kitahara Cari M, Koutros Stella, Kristensen Vessela N, Lacey James V, Lambrechts Diether, Lejbkowicz Flavio, Lindblom Annika, Lush Michael, Mannermaa Arto, Mavroudis Dimitrios, Menon Usha, Murphy Rachel A, Nevanlinna Heli, Obi Nadia, Offit Kenneth, Park-Simon Tjoung-Won, Patel Alpa V, Peng Cheng, Peterlongo Paolo, Pita Guillermo, Plaseska-Karanfilska Dijana, Pylkäs Katri, Radice Paolo, Rashid Muhammad U, Rennert Gad, Roberts Eleanor, Rodriguez Juan, Romero Atocha, Rosenberg Efraim H, Saloustros Emmanouil, Sandler Dale P, Sawyer Elinor J, Schmutzler Rita K, Scott Christopher G, Shu Xiao-Ou, Southey Melissa C, Stone Jennifer, Taylor Jack A, Teras Lauren R, van de Beek Irma, Willett Walter, Winqvist Robert, Zheng Wei, Vachon Celine M, Schmidt Marjanka K, Hall Per, MacInnis Robert J, Milne Roger L, Pharoah Paul D P, Simard Jacques, Antoniou Antonis C, Easton Douglas F, Michailidou Kyriaki

机构信息

Biostatistics Unit, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus, 2371.

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK, CB1 8RN.

出版信息

medRxiv. 2024 Feb 13:2024.02.12.24302043. doi: 10.1101/2024.02.12.24302043.

DOI:10.1101/2024.02.12.24302043
PMID:38410445
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10896416/
Abstract

The 313-variant polygenic risk score (PRS) provides a promising tool for breast cancer risk prediction. However, evaluation of the PRS across different European populations which could influence risk estimation has not been performed. Here, we explored the distribution of PRS across European populations using genotype data from 94,072 females without breast cancer, of European-ancestry from 21 countries participating in the Breast Cancer Association Consortium (BCAC) and 225,105 female participants from the UK Biobank. The mean PRS differed markedly across European countries, being highest in south-eastern Europe and lowest in north-western Europe. Using the overall European PRS distribution to categorise individuals leads to overestimation and underestimation of risk in some individuals from south-eastern and north-western countries, respectively. Adjustment for principal components explained most of the observed heterogeneity in mean PRS. Country-specific PRS distributions may be used to calibrate risk categories in individuals from different countries.

摘要

313 变体多基因风险评分(PRS)为乳腺癌风险预测提供了一个很有前景的工具。然而,尚未对可能影响风险估计的不同欧洲人群的PRS进行评估。在此,我们利用来自参与乳腺癌协会联盟(BCAC)的21个国家的94072名无乳腺癌的欧洲血统女性的基因型数据,以及来自英国生物银行的225105名女性参与者的数据,探索了欧洲人群中PRS的分布情况。欧洲各国的平均PRS差异显著,在东南欧最高,在西北欧最低。使用整个欧洲的PRS分布对个体进行分类,分别会导致高估东南欧一些个体的风险和低估西北欧一些个体的风险。对主成分进行调整可以解释观察到的平均PRS中大部分的异质性。特定国家的PRS分布可用于校准来自不同国家个体的风险类别。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/cf92c05c7000/nihpp-2024.02.12.24302043v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/1f72eff61f23/nihpp-2024.02.12.24302043v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/8b9c05262e82/nihpp-2024.02.12.24302043v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/e437ad97c101/nihpp-2024.02.12.24302043v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/ad95994a15ae/nihpp-2024.02.12.24302043v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/9b633a9519bd/nihpp-2024.02.12.24302043v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/cf92c05c7000/nihpp-2024.02.12.24302043v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/1f72eff61f23/nihpp-2024.02.12.24302043v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/8b9c05262e82/nihpp-2024.02.12.24302043v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/e437ad97c101/nihpp-2024.02.12.24302043v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/ad95994a15ae/nihpp-2024.02.12.24302043v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/9b633a9519bd/nihpp-2024.02.12.24302043v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dac6/10896416/cf92c05c7000/nihpp-2024.02.12.24302043v1-f0006.jpg

相似文献

1
Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction.欧洲血统人群中多基因评分分布的差异:对乳腺癌风险预测的影响。
medRxiv. 2024 Feb 13:2024.02.12.24302043. doi: 10.1101/2024.02.12.24302043.
2
Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction.欧洲血统人群中多基因评分分布差异:对乳腺癌风险预测的影响
Breast Cancer Res. 2024 Dec 29;26(1):189. doi: 10.1186/s13058-024-01947-x.
3
Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.乳腺癌多基因风险评分与肿瘤特征和生存的关联。
J Clin Oncol. 2023 Apr 1;41(10):1849-1863. doi: 10.1200/JCO.22.01978. Epub 2023 Jan 23.
4
Population-specific validation and comparison of the performance of 77- and 313-variant polygenic risk scores for breast cancer risk prediction.基于人群的验证和比较 77 个和 313 个变异多基因风险评分在乳腺癌风险预测中的性能。
Cancer. 2024 Sep 1;130(17):2978-2987. doi: 10.1002/cncr.35337. Epub 2024 May 8.
5
Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort.验证 BOADICEA 模型和一个包含 313 个变异的多基因风险评分在荷兰前瞻性队列中对乳腺癌风险预测的性能。
Genet Med. 2020 Nov;22(11):1803-1811. doi: 10.1038/s41436-020-0884-4. Epub 2020 Jul 6.
6
Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.乳腺癌多基因风险评分与对侧乳腺癌风险。
Am J Hum Genet. 2020 Nov 5;107(5):837-848. doi: 10.1016/j.ajhg.2020.09.001. Epub 2020 Oct 5.
7
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.基于 313 变异的多基因风险评分对携带 BRCA1 或 BRCA2 种系致病性变异的欧洲裔女性对侧乳腺癌风险预测的预测能力。
Genet Med. 2021 Sep;23(9):1726-1737. doi: 10.1038/s41436-021-01198-7. Epub 2021 Jun 10.
8
Polygenic Breast Cancer Risk for Women Veterans in the Million Veteran Program.百万退伍军人计划中女性退伍军人的多基因乳腺癌风险。
JCO Precis Oncol. 2021 Jul 21;5. doi: 10.1200/PO.20.00541. eCollection 2021 Jul.
9
Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry.评估非洲裔裔女性乳腺癌的多基因风险评分。
J Natl Cancer Inst. 2021 Sep 4;113(9):1168-1176. doi: 10.1093/jnci/djab050.
10
Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk.多基因风险评分与传统危险因素联合与乳腺癌风险的相关性。
J Natl Cancer Inst. 2021 Mar 1;113(3):329-337. doi: 10.1093/jnci/djaa056.

本文引用的文献

1
Principles and methods for transferring polygenic risk scores across global populations.多基因风险评分在全球人群中的转移原理和方法。
Nat Rev Genet. 2024 Jan;25(1):8-25. doi: 10.1038/s41576-023-00637-2. Epub 2023 Aug 24.
2
Polygenic scores in cancer.多基因风险评分在癌症中的应用。
Nat Rev Cancer. 2023 Sep;23(9):619-630. doi: 10.1038/s41568-023-00599-x. Epub 2023 Jul 21.
3
Polygenic scoring accuracy varies across the genetic ancestry continuum.多基因评分准确性在遗传祖先连续体上有所差异。
Nature. 2023 Jun;618(7966):774-781. doi: 10.1038/s41586-023-06079-4. Epub 2023 May 17.
4
Polygenic risk scores in cancer screening: a glass half full or half empty?癌症筛查中的多基因风险评分:是半满还是半空?
Lancet Oncol. 2023 Jun;24(6):579-581. doi: 10.1016/S1470-2045(23)00217-6. Epub 2023 May 10.
5
Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.前瞻性验证 BOADICEA 多因素乳腺癌风险预测模型在大型前瞻性队列研究中的应用。
J Med Genet. 2022 Dec;59(12):1196-1205. doi: 10.1136/jmg-2022-108806. Epub 2022 Sep 26.
6
Enhancing the BOADICEA cancer risk prediction model to incorporate new data on , , updates to tumour pathology and cancer incidence.增强 BOADICEA 癌症风险预测模型,纳入新的数据、、更新的肿瘤病理学和癌症发病率数据。
J Med Genet. 2022 Dec;59(12):1206-1218. doi: 10.1136/jmedgenet-2022-108471. Epub 2022 Sep 26.
7
Challenges and Opportunities for Developing More Generalizable Polygenic Risk Scores.开发更具泛化能力的多基因风险评分的挑战与机遇。
Annu Rev Biomed Data Sci. 2022 Aug 10;5:293-320. doi: 10.1146/annurev-biodatasci-111721-074830. Epub 2022 May 16.
8
Polygenic risk scores for prediction of breast cancer risk in Asian populations.多基因风险评分在亚洲人群乳腺癌风险预测中的应用。
Genet Med. 2022 Mar;24(3):586-600. doi: 10.1016/j.gim.2021.11.008. Epub 2021 Dec 15.
9
Generalizability of Polygenic Risk Scores for Breast Cancer Among Women With European, African, and Latinx Ancestry.多基因风险评分在具有欧洲、非洲和拉丁裔血统的女性乳腺癌中的可推广性。
JAMA Netw Open. 2021 Aug 2;4(8):e2119084. doi: 10.1001/jamanetworkopen.2021.19084.
10
Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I).乳腺癌预防与早期检测的个性化风险评估:整合与实施(PERSPECTIVE I&I)
J Pers Med. 2021 Jun 4;11(6):511. doi: 10.3390/jpm11060511.